LXRX
Lexicon Pharmaceuticals Inc
NASDAQ: LXRX · HEALTHCARE · BIOTECHNOLOGY
$1.61
+3.87% today
Updated 2026-04-30
Market cap
$716.02M
P/E ratio
—
P/S ratio
14.38x
EPS (TTM)
$-0.14
Dividend yield
—
52W range
$1 – $2
Volume
2.4M
Lexicon Pharmaceuticals Inc (LXRX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-101.10%
Operating margin
-269.10%
ROE
-39.70%
ROA
-12.70%
Debt/equity
0.48x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $72.80M | $-54.31M | 100.00% | -75.87% | -74.61% |
| 2007 | $50.12M | $-58.79M | 100.00% | -149.56% | -117.31% |
| 2008 | $32.32M | $-76.86M | 100.00% | -298.68% | -237.80% |
| 2009 | $10.70M | $-82.78M | 100.00% | -840.71% | -773.64% |
| 2010 | $4.91M | $-101.78M | 100.00% | -1,950.24% | -2,073.66% |
| 2011 | $1.85M | $-116.22M | 100.00% | -6,170.63% | -6,285.29% |
| 2012 | $1.09M | $-110.21M | -7,482.55% | -9,955.46% | -10,120.39% |
| 2013 | $2.22M | $-104.13M | -3,936.09% | -4,607.16% | -4,686.14% |
| 2014 | $22.85M | $-100.29M | -290.65% | -439.16% | -438.85% |
| 2015 | $130.01M | $-4.68M | 26.79% | 1.13% | -3.60% |
| 2016 | $83.34M | $-141.43M | -96.76% | -164.58% | -169.71% |
| 2017 | $90.33M | $-129.05M | 97.90% | -151.30% | -142.86% |
| 2018 | $63.21M | $-120.55M | 96.06% | -163.39% | -190.71% |
| 2019 | $322.07M | $130.13M | 99.00% | 43.92% | 40.40% |
| 2020 | $24.00M | $-58.57M | 91.96% | -199.21% | -244.11% |
| 2021 | $298000.00 | $-87.76M | -18,371.81% | -29,224.83% | -29,448.99% |
| 2022 | $139000.00 | $-101.94M | -37,681.29% | -72,489.21% | -73,341.01% |
| 2023 | $1.20M | $-177.12M | -4,798.01% | -14,264.95% | -14,710.88% |
| 2024 | $31.08M | $-200.40M | 98.02% | -634.20% | -644.78% |
| 2025 | $49.80M | $-50.34M | 99.45% | -98.21% | -101.08% |